A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYN
Launched by NOVO NORDISK A/S · Nov 15, 2018
Trial Information
Current as of April 25, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Signed informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
- • Male patients at any age with haemophilia B assigned to N9-GP prophylaxis treatment
- • Decision to initiate treatment with commercially available N9-GP has been made by the patient(s)/Legally Authorised Representative(s) (LAR(s)) and the treating physician before and independently from the decision to include the patient in this study
- Exclusion Criteria:
- • Previous participation in this study. Participation is defined as signed informed consent
- • Known or suspected hypersensitivity to N9-GP or related products
- • Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
- • Clinical suspicion or presence of FIX inhibitor at time of inclusion.
Trial Officials
Clinical Reporting Anchor and Disclosure (1452)
Study Director
Novo Nordisk A/S
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company headquartered in Denmark, specializing in the research, development, manufacturing, and marketing of innovative pharmaceuticals, particularly in the fields of diabetes care, obesity treatment, and hormone replacement therapies. With a strong commitment to improving patient outcomes, Novo Nordisk invests significantly in clinical trials to advance scientific knowledge and develop effective therapies. The company is dedicated to sustainability and ethical practices, striving to deliver high-quality healthcare solutions while addressing the evolving needs of patients worldwide. Through collaboration and innovation, Novo Nordisk aims to lead the way in transforming diabetes and other chronic diseases into manageable conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Winnipeg, Manitoba, Canada
Sheffield, , United Kingdom
Toronto, Ontario, Canada
St. John's, Newfoundland And Labrador, Canada
Zürich, , Switzerland
Zagreb, , Croatia
Bruxelles, , Belgium
Oslo, , Norway
Leuven, , Belgium
Edegem, , Belgium
Wien, , Austria
Athens, , Greece
Sheffield, , United Kingdom
Aarhus N, , Denmark
Manchester, , United Kingdom
Aberdeen, , United Kingdom
Cardiff, , United Kingdom
Toronto, Ontario, Canada
Helsinki, , Finland
Bonn, , Germany
Berlin, , Germany
Manchester, , United Kingdom
Hamilton, Ontario, Canada
Plzen, , Czechia
Brno, , Czechia
St. John's, Newfoundland And Labrador, Canada
Bonn, , Germany
Athens, , Greece
Calgary, Alberta, Canada
Edmonton, Alberta, Canada
Winnipeg, Manitoba, Canada
Lisboa, , Portugal
Plzen, , Czechia
Cardiff, , United Kingdom
Athens, , Greece
Wien, , Austria
Bruxelles, , Belgium
Berlin, , Germany
Athens, , Greece
Oslo, , Norway
Lisboa, , Portugal
Calgary, Alberta, Canada
Edmonton, Alberta, Canada
Hamilton, Ontario, Canada
Hamilton, Ontario, Canada
Zagreb, , Croatia
Brno, , Czechia
Aarhus N, , Denmark
Helsinki, , Finland
Lisboa, , Portugal
Aberdeen, , United Kingdom
Bonn, , Germany
Berlin, , Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials
Related Blog Entries
View all
